These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 19877981)

  • 41. Quetiapine addition in methylphenidate treatment-resistant adolescents with comorbid ADHD, conduct/oppositional-defiant disorder, and aggression: a prospective, open-label study.
    Kronenberger WG; Giauque AL; Lafata DE; Bohnstedt BN; Maxey LE; Dunn DW
    J Child Adolesc Psychopharmacol; 2007 Jun; 17(3):334-47. PubMed ID: 17630867
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Risperidone-to-methylphenidate switch reaction in children: three cases.
    Sabuncuoglu O
    J Psychopharmacol; 2007 Mar; 21(2):216-9. PubMed ID: 17329303
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Stimulant treatment for attention-deficit hyperactivity disorder and risk of developing substance use disorder.
    Groenman AP; Oosterlaan J; Rommelse NN; Franke B; Greven CU; Hoekstra PJ; Hartman CA; Luman M; Roeyers H; Oades RD; Sergeant JA; Buitelaar JK; Faraone SV
    Br J Psychiatry; 2013 Aug; 203(2):112-9. PubMed ID: 23846996
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-acting methylphenidate has an effect on aggressive behavior in children with attention-deficit/hyperactivity disorder.
    Sinzig J; Döpfner M; Lehmkuhl G; ; Uebel H; Schmeck K; Poustka F; Gerber WD; Günter M; Knölker U; Gehrke M; Hässler F; Resch F; Brünger M; Ose C; Fischer R
    J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):421-32. PubMed ID: 17822338
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
    Dittmann RW; Schacht A; Helsberg K; Schneider-Fresenius C; Lehmann M; Lehmkuhl G; Wehmeier PM
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Canadian guidelines on pharmacotherapy for disruptive and aggressive behaviour in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, or conduct disorder.
    Gorman DA; Gardner DM; Murphy AL; Feldman M; Bélanger SA; Steele MM; Boylan K; Cochrane-Brink K; Goldade R; Soper PR; Ustina J; Pringsheim T
    Can J Psychiatry; 2015 Feb; 60(2):62-76. PubMed ID: 25886657
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antipsychotics for children and young adults: a comparative effectiveness review.
    Seida JC; Schouten JR; Boylan K; Newton AS; Mousavi SS; Beaith A; Vandermeer B; Dryden DM; Carrey N
    Pediatrics; 2012 Mar; 129(3):e771-84. PubMed ID: 22351885
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons.
    Fraguas D; Correll CU; Merchán-Naranjo J; Rapado-Castro M; Parellada M; Moreno C; Arango C
    Eur Neuropsychopharmacol; 2011 Aug; 21(8):621-45. PubMed ID: 20702068
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy.
    Blader JC; Schooler NR; Jensen PS; Pliszka SR; Kafantaris V
    Am J Psychiatry; 2009 Dec; 166(12):1392-401. PubMed ID: 19884222
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Metabolic Effects of Antipsychotics on Adiposity and Insulin Sensitivity in Youths: A Randomized Clinical Trial.
    Nicol GE; Yingling MD; Flavin KS; Schweiger JA; Patterson BW; Schechtman KB; Newcomer JW
    JAMA Psychiatry; 2018 Aug; 75(8):788-796. PubMed ID: 29898210
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Treatment of Severe Childhood Aggression Study: 12 Weeks of Extended, Blinded Treatment in Clinical Responders.
    Findling RL; Townsend L; Brown NV; Arnold LE; Gadow KD; Kolko DJ; McNamara NK; Gary DS; Kaplin DB; Farmer CA; Kipp H; Williams C; Butter EM; Bukstein OG; Rice R; Buchan-Page K; Molina BS; Aman MG
    J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):52-65. PubMed ID: 28212067
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Review of attention-deficit/hyperactivity disorder comorbid with oppositional defiant disorder.
    Hazell P
    Australas Psychiatry; 2010 Dec; 18(6):556-9. PubMed ID: 21117844
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Quetiapine versus other atypical antipsychotics for schizophrenia.
    Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
    Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Stimulant and atypical antipsychotic medications for children placed in foster homes.
    Linares LO; Martinez-Martin N; Castellanos FX
    PLoS One; 2013; 8(1):e54152. PubMed ID: 23326588
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Psychopharmacologic treatment of aggressive preschoolers: a chart review.
    Staller JA
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):131-5. PubMed ID: 17007977
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Real-World Data on the Adverse Metabolic Effects of Second-Generation Antipsychotics and Their Potential Determinants in Adult Patients: A Systematic Review of Population-Based Studies.
    Bernardo M; Rico-Villademoros F; García-Rizo C; Rojo R; Gómez-Huelgas R
    Adv Ther; 2021 May; 38(5):2491-2512. PubMed ID: 33826090
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Pharmacotherapy of attention-deficit/hyperactivity disorder (ADHD) and comorbid disorders].
    Wiesegger G; Kienbacher C; Pellegrini E; Scheidinger H; Vesely C; Bangerl W; Friedrich M
    Neuropsychiatr; 2007; 21(3):187-206. PubMed ID: 17915180
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reduced salivary cortisol in children with comorbid Attention deficit hyperactivity disorder and oppositional defiant disorder.
    Kariyawasam SH; Zaw F; Handley SL
    Neuro Endocrinol Lett; 2002 Feb; 23(1):45-8. PubMed ID: 11880861
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.